{"database": "lobbying", "table": "lobbying_activities", "rows": [[1223165, "76b037f1-d914-40a5-8ac0-cb9f3fe23922", "Q1", "HOLLAND & KNIGHT LLP", 18466, "SHIRE PHARMACEUTICALS, INC", 2012, "first_quarter", "HCR", "Drug shortage legislation:  Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296);  Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products.", "HOUSE OF REPRESENTATIVES,SENATE", 0, 0, "2012-04-03T13:05:43.727000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1223165"], "units": {}, "query_ms": 0.275676604360342, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}